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Background/Aims: Endoscopic resection is a standard 
treatment for stage T1a esophageal cancer, with esophagec-
tomy or radical radiation therapy (RT) performed for stage 
T1b lesions. This study aimed to compare treatment out-
comes of each modality for clinical stage T1 esophageal can-
cer. Methods: In total, 179 patients with clinical T1N0M0-
stage esophageal cancer treated from 2006 to 2016 were 
retrospectively evaluated. Sixty-two patients with clinical T1a-
stage cancer underwent endoscopic resection. Among 117 
patients with clinical T1b-stage cancer, 82 underwent esoph-
agectomy, and 35 received chemoradiotherapy or RT. We 
compared overall survival (OS) and recurrence-free survival 
(RFS) rates for each treatment modality. Results: The medi-
an follow-up time was 32 months (range, 1 to 120 months). 
The 5-year OS and RFS rates for patients with stage T1a 
cancer receiving endoscopic resection were 100% and 85%, 
respectively. For patients with stage T1b, the 5-year OS and 
RFS rates were 78% and 77%, respectively, for the esopha-
gectomy group; 80% and 44%, respectively, for the RT alone 
group; and 96% and 80%, respectively, for the chemoradia-
tion group. The esophagectomy group showed significantly 
higher RFS than the RT alone group (p=0.04). There was no 
significant difference in RFS between the esophagectomy 
and chemoradiation groups (p=0.922). Grade 4 or higher 
treatment-related complications occurred in four patients 
who underwent esophagectomy. Conclusions: Endoscopic 
resection appeared to be an adequate treatment for patients 
with T1a-stage esophageal cancer. The multidisciplinary 
approach involving chemoradiation was comparable to 
esophagectomy in terms of survival outcome without serious 
complications for T1b-stage esophageal cancer. (Gut Liver 
2019;13:315-324)
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INTRODUCTION
Esophageal cancer is one of the most common and aggressive 
cancers worldwide. It is a frequently diagnosed cancer, with ap-
proximately 460,000 new cases and 400,000 deaths worldwide 
in 2012.1 The incidence of this disease has increased dramati-
cally during the past 3 decades.2 With this increasing incidence, 
the overall prognosis of patients with esophageal cancer re-
mains poor, with a 5-year survival rate of 14%.3 However, with 
the increasing use of endoscopic surveillance and early detec-
tion, early-stage cancers are being diagnosed more frequently. 
In early-stage (T1N0M0) esophageal cancer, lesions are limited 
to the mucosa (T1a) or submucosa (T1b), and this diagnosis ac-
counts for approximately 20% of all initial diagnoses.4 These 
early-stage cancers present the best opportunity for a cure at di-
agnosis, which can affect the overall prognosis of all esophageal 
cancers. The 5-year survival rate can be as high as 85%; a stark 
contrast to 10% when diagnosed at an advanced stage.5
Esophagectomy has been the standard treatment for T1b 
esophageal cancer, although with some debate. Recently, there 
has been increasing interest in endoscopic therapies for lesions 
of this stage. These include ablative techniques, such as pho-
todynamic therapy and endoscopic mucosal resection (EMR).6,7 
Radiation therapy (RT) can also be used for superficial esopha-
geal cancer, and favorable outcomes have also been reported 
for this noninvasive treatment.8 Moreover, RT has undergone 
notable advances during the past decade. Three-dimensional 
(3D) conformal RT, intensity-modulated radiation therapy (IMRT) 
based on computed tomography (CT) images and multileaf col-
limators have contributed to the accurate delivery of high doses 
to the target, sparing normal tissues. However, the role of de-
finitive RT in treating superficial esophageal cancer compared 
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with other treatment modalities, such as esophagectomy and 
endoscopic therapies, has not yet been elucidated.
In Yonsei Cancer Center, we perform esophagectomy, endo-
scopic therapies, or RT for T1 esophageal cancers according to 
the physicians’ decision after a multidisciplinary discussion. This 
study aimed to compare the outcomes of each treatment modal-
ity while examining the experience of a single institution with 
the treatment of early-stage esophageal cancers. 
MATERIALS AND METHODS
1. Patients 
We retrospectively identified 208 patients who received treat-
ments for clinical T1N0M0 esophageal cancer between February 
2006 and December 2016 at Severance Hospital, Seoul, Korea. 
Among 208 patients, 27 with other malignancies and two with 
involvement of the esophagogastric junction were excluded. A 
total of 179 patients were included in the final analysis. Data 
were collected from patients’ medical and surgical records and 
a departmental database (IRB exemption number: 2018-3377-
001). 
2. Treatment
Before the treatment decision, endoscopic ultrasonography 
(EUS) was performed for all patients to evaluate the depth of 
cancer invasion. The depth of tumor infiltration for clinical T 
categorization was determined by EUS based on the deepest 
invasion depth. According to the American Joint Committee on 
Cancer guidelines 7th edition, the depth of invasion was catego-
rized as T1a if the tumor invaded the lamina propria or mus-
cularis mucosae and as T1b if there was submucosal invasion. 
Careful examination of the ultrasound image revealed the pres-
ence of abnormal or enlarged lymph nodes that were likely to 
harbor cancer and occasionally signs of distant spread, such as 
a lesion in the surrounding organs. In addition, the nodal status 
and occurrence of distant metastasis were evaluated by CT and 
positron emission tomography-CT. 
The treatment decision was made fundamentally according 
to the National Comprehensive Cancer Network guidelines for 
these stages after a multidisciplinary discussion. Physicians 
preferentially considered endoscopic therapy for T1a tumors and 
esophagectomy for T1b tumors. RT was performed in cases of 
surgical difficulties because of the tumor location, advanced pa-
tient age, or comorbidities and for patients who refused surgery. 
Patients who were initially diagnosed as having clinical T1a 
esophageal cancer but diagnosed with pathological T1b disease 
after endoscopic therapy and received complete surgery or RT 
were included in this study. These patients were examined sepa-
rately from those who were finally diagnosed with pT1a disease.
1) Endoscopic therapy 
Endoscopic resection was conducted by EMR consisting of 
EMR using a transparent cap procedure, EMR with precut-
ting, and endoscopic submucosal dissection (ESD) with various 
knives, such as a hook knife, IT knife-2, or dual knife. The de-
tailed methods used for endoscopic resection were described in 
our institution’s previous paper.9
2) Radiotherapy
The total dose was determined by a radiation oncologist con-
sidering the patient’s condition (e.g., age, performance status, 
and coexisting disease) and tolerance dose of adjacent normal 
tissues (e.g., spinal cord, lungs, and heart). RT was delivered 5 
days a week at 1.8 to 2.1 Gy (median, 1.8 Gy) per fraction. The 
total dose ranged from 50.4 to 64.0 Gy (median, 63.0 Gy) in 28 
to 35 fractions. The gross tumor volume (GTV) was defined for 
primary and nodal disease and was drawn on axial planning 
CT images using the EUS-derived ab oral distances and EUS/
CT findings as references. The clinical target volume (CTV) was 
defined as the GTV plus a 3 to 5 cm margin in the longitudinal 
direction and a 0.5 to 1 cm margin in the lateral and antero-
posterior directions. The planning target volume was defined 
as the CTV plus an additional 0.3 to 0.5 cm margin to account 
for setup error and internal organ motion. The RT modality 
(3D conformal RT or IMRT) was selected considering the tumor 
location and temporal changes. The proportion of patients who 
underwent 3D conformal RT was 82.9%, and that of patients 
who underwent IMRT was 17.1%. 
Rather than RT alone, concurrent chemoradiotherapy (CCRT) 
was performed for patients with a good general condition. For 
CCRT, two courses of chemotherapy were administered during 
RT on days 1 to 5 at 3-week intervals. Chemotherapy consisted 
of 5-fluorouracil (700 mg/m2 of body surface area per day by 
120-hour infusion) and cisplatin (15 mg/m2 of body surface 
area per day intravenously). 
3) Esophagectomy
For patients with middle and lower esophageal cancers, a 
two-field lymph node dissection and intrathoracic esophagogas-
trostomy were performed using the whole stomach as a conduit, 
and anastomosis was performed with a 28-mm end-to-end 
anastomosis stapler. For patients with upper esophageal cancer, 
three-field lymph node dissection was routinely performed. If 
intrathoracic esophagogastrostomy was possible, intrathoracic 
anastomosis was performed using the entire stomach. For all 
others, cervical esophagogastrostomy with a gastric tube was 
performed. The stomach was positioned in the posterior medi-
astinum. The detailed methods are available in another previous 
report.10
4) Salvage treatment
At a multidisciplinary clinic, the optimal treatment was dis-
cussed. Reirradiation was also considered when the interval 
from previous RT was long and the radiation doses were ac-
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ceptable for the adjacent normal organs. In contrast, surgical 
resection was considered when reirradiation was thought to be 
difficult or pathological confirmation was required. Only local 
or regional recurrence was considered for salvage treatment. 
However, systemic chemotherapy was performed after local 
treatment if distant metastasis occurred.
3. Evaluation of response
Patients who underwent endoscopic therapy or RT were fol-
lowed using endoscopy with biopsies, CT, and EUS every 6 
months after treatment for 3 years and every year thereafter. 
The opinion of the experienced physicians who performed the 
endoscopy was also important for discriminating between true 
recurrence and treatment-related changes. A complete response 
(CR) was defined when no residual tumor findings were seen 
in any examination. A partial response (PR) was defined when 
residual tumor findings were identified by all examinations.
Patients who underwent esophagectomy were followed using 
CT every 6 months after treatment for 3 years and every year 
thereafter. An endoscopic evaluation was performed every year 
and when abnormalities were seen on follow-up CT.
Patterns of failure were classified according to the recurrence 
sites, as follows. Local recurrence was defined as recurrence in 
the esophagus, and regional recurrence was defined as recur-
rence in regional nodes. Distant recurrence was defined as re-
currence at any other site.
4. Statistical analysis
Overall survival (OS) was defined as the time from initial 
diagnosis to death from any cause or the last follow-up. Recur-
rence-free survival (RFS) was measured from the initial diagno-
sis to any recurrence or the last follow-up. Both the OS and RFS 
rates were calculated using the Kaplan-Meier method, and the 
significance of differences in survival was assessed using the 
log-rank test. The Cox regression was used for the identification 
of independent prognostic factors by multivariate analysis. Fur-
thermore, the chi-square test was used to compare categorical 
variables, and the t-test was used to compare continuous vari-
ables. A p-value <0.05 was considered statistically significant. 
SPSS version 23.0 (IBM Corp., Armonk, NY, USA) was used for 
all statistical analyses.
RESULTS
1. Patients
Among the 179 patients who met the inclusion criteria in 
this study, 62 were initially diagnosed with cT1a esophageal 
cancer, and the rest were diagnosed with cT1b esophageal can-
cer. As shown in Fig. 1, 62 patients first underwent endoscopic 
resection (28 by EMR, 34 by ESD). Further treatments were 
performed according to the pathological results of subsequent 
endoscopic tests. A total of 14 patients were finally diagnosed 
with pT1b esophageal cancer; half of them received adjuvant 
RT, and the rest underwent complete esophagectomy. Among 
117 patients with cT1b esophageal cancer, 82 underwent esoph-
agectomy and 35 received CCRT (n=25) or RT alone (n=10). 
The baseline characteristics and cancer-related features of the 
four groups (EMR/ESD, esophagectomy, CCRT, and RT alone) 
are summarized in Table 1. There was a significant difference 
in age and tumor location according to the treatment method 
(p=0.003 and p<0.001, respectively). The median patient age 
(years) was 68 in the endoscopy group, 64 in the esophagecto-
my group, 66 in the CCRT group, and 75 in the RT alone group. 
The median patient age was significantly higher in the RT alone 
group than in the other groups. There were significantly more 
tumors in the cervical or upper thoracic area in the CCRT group 
than in the other groups. Because performing laryngopharyn-
goesophagectomy for cervically located tumors might subse-
quently reduce the quality of life, we selected CCRT or RT alone 
for patients with these lesions. Otherwise, no other significant 
differences were found in the patient characteristics.
2. Treatment outcomes 
The median follow-up period among all patients was 32 
months (range, 1 to 120 months). The 5-year OS and RFS rates 
of all patients were 86% and 77%, respectively (Fig. 2A). All 
62 cT1a
48 No further Tx
48 pT1a 14 pT1b
7 Adjuvant RT
7 Complete
esophagectomy
117 cT1b
62 EMR or ESD 82 Esophagectomy 35 CCRT or RT alone
Cervical lesion
Refused operation
Poor performance Fig. 1. Treatment flow of all patients 
(n=179).
cT, clinical T stage; EMR, endoscop-
ic mucosal resection; ESD, endo-
scopic submucosal resection; CCRT, 
concurrent chemoradiotherapy; RT, 
radiation therapy; pT, pathologic T 
stage; Tx, therapy.
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Table 1. Patient Characteristics
Variable EMR/ESD Esophagectomy CCRT RT alone p-value
Sex 0.607
   Male 57 (92) 75 (92) 25 (100) 10 (100)
   Female 5 (8) 7 (8) 0 0
Age, yr  68 (44–82) 64 (50–86) 66 (55–85) 75 (65–82) 0.003
Histology 0.834
   SCCa 61 (98) 81 (99) 25 (100) 10 (100)
   Adenosquamous 1 (2) 1 (1) 0 0
cT stage <0.001
   cT1a  62 (100) 0 0 0
   cT1b 0 82 (100) 25 (100) 10 (100)
Tumor location <0.001
   Cervical 0 0 5 (20) 1 (10)
   Upper thoracic  6 (10) 10 (12) 8 (32) 0
   Middle thoracic 17 (27) 34 (42) 4 (16) 3 (30)
   Lower thoracic 39 (63) 38 (46) 8 (32) 6 (60)
Data are presented as number (%) or median (range).
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; SCCa, squa-
mous cell carcinoma; cT stage, clinical T stage.
Fig. 2. Comparison of Kaplan-Meier overall survival (OS) curves; (A) OS and recurrence-free survival (RFS) of all patients, (B) OS and RFS of pa-
tients with cT1a lesions after endoscopic resection, (C) OS and (D) RFS of patients with cT1b lesions according to the treatment group. 
CCRT, concurrent chemoradiotherapy; RT, radiotherapy.
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patients with T1a lesions underwent endoscopic therapy (EMR/
ESD). Except for the 14 patients who were diagnosed with path-
ological T1b disease through endoscopic therapy, the 5-year 
OS and RFS rates in the EMR/ESD group were 100% and 85%, 
respectively (Fig. 2B). Patients diagnosed with T1b disease were 
excluded from the outcome analysis of the EMR/ESD group be-
cause they received salvage treatment. Patients with T1b lesions 
underwent esophagectomy, CCRT, or RT. The 5-year OS and 
RFS rates were 78% and 77%, respectively, in the esophagecto-
my group, 96% and 80%, respectively, in the CCRT group, and 
80% and 44%, respectively, in the RT alone group (Fig. 2C and 
D). There was no significant difference in OS according to the 
treatment modality in patients with T1b disease (p=0.405). The 
RFS rate was significantly higher in the esophagectomy group 
than in the RT alone group (p=0.04). There was no significant 
difference in RFS between the esophagectomy and CCRT groups 
(p=0.922). There were 35 patients with pathologically diagnosed 
T1a disease after surgery. Excluding these patients, the esopha-
gectomy group had a 5-year OS rate of 63% and a 5-year RFS 
rate of 66%. At this time, no significant differences were found 
62 EMR or ESD
48 Diagnosed T1a CR
1 Alive with disease
6 Alive without disease
1 Alive with disease
6 Alive without disease
1 Alive with disease
46 Alive without disease
1 Alive with disease1 Local failure
1 Regional failure
6 CR
1 Local failure
6 CR
1 Distant failure
2 Recurrence
7 Adjuvant RT
7 Adjuvant surgery
14 Diagnosed T1b
A
82 Esophagectomy
1 Alive with disease
1 Alive with disease
3 Died of disease
1 Alive with disease
68 Alive without disease
3 Died of other cause
3 Distant failure
B
CR
1 Died of disease
1 Died of other cause
4 Regional failure
1 Local failure
8 Recurrence
71 NED
3 Treatment-related death
Fig. 3. Flow of treatment outcomes for each treatment group. Outcome for endoscopic therapy group (A), esophagectomy group (B), concurrent 
chemoradiotherapy (CCRT) group (C), radiotherapy (RT) group (D).
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal resection; CR, complete response; NED, no evidence of disease; PR, partial re-
sponse.
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in OS or RFS among the esophagectomy, CCRT, and RT alone 
groups. Regarding OS, age, T stage, and treatment modality 
were significant factors in both the univariate and multivariate 
analyses (p=0.007, p=0.056, and p=0.026, respectively). Regard-
ing RFS, there were no significant factors in the univariate or 
multivariate analysis (Supplementary Table 1). 
In the EMR/ESD group (n=62), 48 patients were diagnosed 
with pT1a disease and 14 patients were diagnosed with pT1b 
disease. Of the 48 patients diagnosed with pT1a disease, 46 are 
alive without disease after no adjuvant treatment, and two ex-
perienced local or regional recurrence. Seven of 14 patients with 
pT1b disease underwent adjuvant RT, and seven underwent ad-
juvant surgery sequentially. Most patients, except the two with 
recurrence, have maintained CR and are alive without recur-
rence (Fig. 3A).
In the esophagectomy group (n=82), all esophageal cancers 
were completely removed through surgery. However, three pa-
tients died from treatment-related causes (sepsis after pneumo-
nia or esophageal perforation). Otherwise, 71 patients are alive 
without any recurrence. Eight patients experienced recurrence 
(local=1, regional=4, and distant=3), and half of them died after 
disease progression (Fig. 3B).
In the CCRT group (n=25), 18 patients had CR, and seven had 
PR. Of the patients with CR, all are alive without disease, except 
one who died of another medical cause. Of the patients with PR, 
none showed disease progression, and all are alive even without 
any additional treatment, except one who died of another medi-
cal cause (Fig. 3C). 
In the RT alone group (n=10), half of the patients had CR, and 
the other half had PR. Of the patients with CR, only one devel-
oped regional recurrence, and the rest are alive with or without 
the disease. Of the patients with PR, three patients experienced 
25 CCRT
18 CR
2 Alive with disease
13 Alive without disease
1 Died of other cause
1 Alive without disease
1 Alive with disease
6 Alive with disease
1 Died of other cause
2 Local failure
C
2 Regional failure
4 Recurrence
14 NED
7 PR 7 No progression
10 RT
5 CR
1 Alive without disease
4 Alive without disease
1 Died of disease
2 Alive with disease
1 Alive with disease
1 Died of disease
1 Regional failure
D
1 Local failure
1 Recurrence
4 NED
5 PR
1 Regional failure
1 Distant failure
2 No progression
3 Progression
Fig. 3. Continued.
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recurrence (local=1, regional=1, and distant=1), and the patient 
with distant recurrence died of the disease (Fig. 3D). An over-
view of the outcomes in each treatment subgroup is shown in 
Fig. 3.
3. Patterns of failure
Table 2 lists the site of the first recurrence for patients in the 
four subgroups. Twenty of the 179 patients experienced recur-
rence. The group with the highest rate of recurrence was the 
RT alone group (7% in the EMR/ESD group, 9% in the esopha-
gectomy group, 16% in the CCRT group, and 40% in the RT 
alone group). In the EMR/ESD group, although the overall rate 
of recurrence was low (n=4), local recurrence occurred in three 
patients (75%), and regional recurrence occurred in one patient 
(25%). In the esophagectomy group, regional recurrence was 
the most frequent recurrence pattern (50%), followed by distant 
(38%) and local recurrence (12%). In the CCRT group, half of 
the overall instances of recurrence were local, and the rest were 
regional. There were no instances of distant recurrence after 
CCRT. In the RT alone group, the regional recurrence rate was 
the most frequent, at 50%, followed by local (25%) and distant 
recurrence (25%).
4. Complications
Table 3 lists the complications of patients in the three sub-
groups, which included only T1b lesions. The overall rates of 
acute complications were 34%, 52%, and 50% in the esopha-
gectomy, CCRT, and RT alone groups, respectively. The most 
common acute complications were esophageal stricture (17%) 
in the esophagectomy group, esophagitis (52%) in the CCRT 
group, and esophagitis (40%) in the RT alone group. Grade 4 or 
higher complications only developed in four patients (3%) in 
the esophagectomy group. Three patients had pneumonia at a 
median of 1 month after surgery, and one patient experienced 
perforation 1 week after surgery. Three patients died after these 
complications. Otherwise, all complications were grade 2, except 
two complications in the CCRT group and four complications in 
the RT alone group (all manageable esophagitis during RT). Late 
complications were only found in the esophagectomy group 
(24%), most of which were esophageal stricture, dysphagia, or 
regurgitation. 
Table 2. Patterns of Failure According to the Treatment Group
Type EMR/ESD Esophagectomy CCRT RT alone
Local recurrence 3 (5) 1 (1) 2 (8) 1 (10)
Regional recurrence 1 (2) 4 (5) 2 (8) 2 (20)
Distant metastasis 0 3 (4) 0 1 (10)
Total 4 (7) 8 (9) 4 (16) 4 (40)
Data are presented as number (%).
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal resection; CCRT, concurrent chemoradiotherapy; RT, radiation therapy.
Table 3. Acute and Late Complication Rates According to Treatment 
Group in Patients with T1b Lesions 
Complication  Esophagectomy CCRT RT alone
Acute
   Esophagitis
      Grade 2 0 11 (44) 0
      Grade 3 0 2 (8) 4 (40)
      Grade 4 or 5 0 0 0
   Esophageal stricture
      Grade 2 1 (1) 0 0
      Grade 3 13 (16) 0 0
      Grade 4 or 5 0 0 0
   Pneumonia
      Grade 2 0 0 0
      Grade 3 2 (2) 0 0
      Grade 4 or 5 3 (4) 0 0
   Other complication
      Grade 2 2 (2) 0 1 (10)
      Grade 3 6 (7) 0 0
      Grade 4 or 5 1 (1) 0 0
Late
   Esophagitis
      Grade 2 0 0 0
      Grade 3 0 0 0
      Grade 4 or 5 0 0 0
   Esophageal stricture
      Grade 2 5 (6) 0 0
      Grade 3 10 (12) 0 0
      Grade 4 or 5 0 0 0
   Pneumonia
      Grade 2 0 0 0
      Grade 3 0 0 0
      Grade 4 or 5 0 0 0
   Other complication
      Grade 2 4 (5) 0 0
      Grade 3 1 (1) 0 0
      Grade 4 or 5 0 0 0
Data are presented as number (%).
CCRT, concurrent chemoradiotherapy; RT, radiation therapy.
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DISCUSSION
In this study, we compared the outcomes of endoscopic ther-
apy, esophagectomy, CCRT, and RT in patients with early-stage 
esophageal cancer. First, patients with T1a esophageal cancer 
had a good prognosis with endoscopic eradication therapies. 
Second, esophagectomy did not improve OS compared with 
other noninvasive therapies in patients with T1b esophageal 
cancer. Esophagectomy prolonged RFS significantly compared 
with RT alone; however, there was no notable difference com-
pared with CCRT. The outcomes of CCRT and RT should be as-
sessed further, given that more patients of an advanced age or 
with a poor performance status are treated with either CCRT or 
RT rather than surgery.
Traditionally, the gold standard approach to the management 
of early-stage esophageal cancer has been esophagectomy, 
either alone or in combination with chemotherapy and/or RT. 
Although shown to improve survival, this approach has been 
associated with significant risks, such as surgical complications 
(e.g., anastomotic leak, infection, pneumonia, or stenosis) and 
even mortality. Recent efforts to improve the outcomes of early-
stage esophageal cancer treatment, the primary goal of which 
is cure, have focused on the development of less invasive endo-
scopic treatments designed to destroy or remove cancerous le-
sions in the esophageal wall while sparing healthy tissue. These 
treatments have been used either alone or in combination with 
other techniques without compromising oncologic outcomes. As 
in our results, grade 4 or higher complications, including pneu-
monia and esophageal perforation, have only been observed 
in the esophagectomy group, and no severe late complications 
have appeared in patients undergoing CCRT or RT. 
Currently, the National Cancer Institute recommends surgery 
as the standard treatment for T1b esophageal cancer, and this 
recommendation is based on the observation that T1b esopha-
geal squamous cell carcinoma has a high incidence of lymph 
node metastasis.11 In our study, the patterns of failure data 
showed that the overall recurrence rate in patients with T1a 
disease was as low as 7%. In the esophagectomy group, the lo-
cal recurrence rate was 1%, the regional recurrence rate was 
5%, and the distant metastasis rate was 4%, which means that 
surgical resection is good for local control. In the CCRT group, 
the local and regional recurrence rates were both 8%, with no 
distant metastasis. In the RT alone group, the regional recur-
rence rate was as high as 20%, and the local and distant metas-
tasis rates were both 10%. Comparing the CCRT group with the 
RT alone group, the absence of distant metastasis in the CCRT 
group indicates that the combination of chemotherapy with RT 
might be effective enough for systemic control. Considering that 
patients with T1b lesions had a regional recurrence rate of 7.6%, 
we recommend including the regional lymph nodes in the RT 
field, rather than simply irradiating the primary mass. Chemo-
therapy for systemic control should also be considered.
In patients with T1a disease, the 5-year OS and RFS rates 
were 100% and 85%, respectively. Among patients with T1b 
disease, there was no significant difference in outcome between 
patients who underwent esophagectomy and those who under-
went CCRT. This suggests that CCRT is sufficiently comparable 
to esophagectomy even after considering possible selection bias, 
which may have occurred because more patients with a poor 
condition were included in the CCRT or RT alone group. 
One previous study demonstrated the superior outcome of 
esophagectomy in patients with cT1 esophageal cancer.11 Mat-
sumoto et al.11 compared the outcomes of 29 patients with radi-
cal esophagectomy and 38 patients with definitive RT. Although 
there was no difference in the OS rate, the RFS rate was signifi-
cantly higher in the surgery group than in the radiation group 
(5-year RFS 62% vs 39%, p=0.005). In particular, a significantly 
higher RFS rate was achieved in patients with tumors that in-
vaded the submucosa. However, before concluding that surgery 
is the most appropriate treatment for cT1 esophageal cancer, 
it should be noted that the authors did not distinguish patients 
who underwent RT only from patients who underwent CCRT. 
Considering that the RT alone group showed an inferior result 
in our paper, the results of Matsumoto’s study are considered to 
be similar to the results of our study. The outcome of CCRT was 
superior to that of RT alone in esophageal cancer according to 
a previous prospective randomized trial.12 Therefore, we propose 
that CCRT should be in an equal position rather than considered 
a simple alternative treatment, based on the results of those 
studies and other favorable data supporting RT.13,14 
After esophagectomy, 35 patients were diagnosed with 
pathological T1a disease, but not T1b. When the outcome of the 
esophagectomy group was excluded except for these patients, it 
showed a poorer outcome than before, which is probably to be 
expected. This outcome was not statistically significant when 
compared with those of the other groups. In other words, the 
significant differences observed in RFS for the RT alone group 
disappeared and showed an inferior tendency, although not 
significantly so, compared with the CCRT group. However, in 
the CCRT and RT alone groups, T1b disease was diagnosed us-
ing EUS, but there were actually patients with T1a disease in the 
group. Therefore, it is difficult to conclude that esophagectomy 
is inferior to CCRT. 
When we performed multivariate analysis in this study, the 
factors significantly associated with OS were age, T stage, and 
treatment modality. T stage has been reported as a significant 
factor in several studies;1,15 treatment modality could also be a 
significant factor because there was a difference in the baseline 
characteristics according to treatment modality, which was 
related to T stage. Conversely, there might be no significant dif-
ference in OS according to treatment modality when patients 
with the same stage disease are analyzed. Other studies have 
shown that T stage, age, facility, and follow-up frequency in 
early-stage esophageal cancer are significantly associated with 
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outcome.15,16 Most of these studies were similar to ours; this 
means that our cohort can be a representative cohort of early-
stage esophageal cancer patients. Moreover, our study was a 
single-institution study with no differences in follow-up sched-
ules or facilities among the treatment groups. 
There are several limitations to this study. First, there could 
be a selection bias because of the retrospective nature of this 
study. Although the main purpose of this study was to compare 
each treatment modality in early-stage esophageal cancer, there 
was a trend to treat patients with T1b disease with esophagec-
tomy unless the patient refused surgery. Definitive CCRT was 
performed because of the difficulty of surgery when the lesion 
was located at a cervical level. Furthermore, if the patient had 
any medical comorbidities or a poor performance status, the 
physicians decided to perform CCRT or RT. Physicians’ prefer-
ences or differences in patient characteristics could affect the 
treatment outcomes unexpectedly. Second, this study could not 
analyze the effect of RT technique development on the treat-
ment outcome. Recently, our institution has been treating many 
patients with esophageal cancer using IMRT. This study in-
cluded patients from the past, most of whom were treated with 
3-dimensional (3D)-conformal radiation therapy (3D-conformal 
radiation therapy 82.8% vs IMRT 17.2%). We could not find 
any difference according to RT modality in this small group of 
patients. Lastly, we performed response evaluation using biopsy 
for patients who underwent definitive CCRT or RT. However, 
because endoscopic biopsy after CCRT/RT sometimes shows low 
sensitivity/specificity in the detection of recurring carcinoma, 
this may have caused some bias in the outcomes.
Nevertheless, this study has strength in that it analyzed the 
outcome of patients with early esophageal cancer who received 
treatment with various modalities based on the medical records 
of a single institution. Patients were included in this study ac-
cording to stricter eligibility criteria than those of previous 
studies, which in turn enhanced the homogeneity of this study. 
In our institution, many patients with esophageal cancer are 
referred to a multidisciplinary clinic, where the optimal treat-
ment based on institutional policy is selected. In addition, un-
like previous studies, a more precise comparative study could be 
performed by comparing the patient subgroups. To overcome 
the limitations caused by the small number of patients receiv-
ing each treatment and perform a more structured comparative 
study, the Korean Radiation Oncology Group plans to perform a 
multi-institutional retrospective study on the optimal treatment 
policy for early-stage esophageal cancer.
In conclusion, we assessed the clinical outcomes of clinical 
T1N0M0 esophageal cancer patients according to each different 
treatment modality. In patients with T1a disease, endoscopic 
therapy was found to be a satisfactory treatment. In patients 
with T1b disease, CCRT and esophagectomy showed a com-
parably good outcome, although RT alone showed an inferior 
outcome compared with the modalities. However, the esopha-
gectomy group included some patients with ≥ grade 4 compli-
cations and included patients with more favorable conditions 
than those in the other groups, which might have caused selec-
tion bias. Considering those results, CCRT should be considered 
an alternative to esophagectomy for the treatment of patients 
with T1b disease. To clarify our findings, further studies with a 
randomized controlled design or larger cohort are warranted. 
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